Waters Corporation (WAT) Earnings Call Transcript & Summary

Vijay Kumar, the Life Science Tools and Medtech Analyst at Evercore. A pleasure to have with us Waters. We have CEO, Dr. Udit Batra, with us this morning. And from Investor Relations, we have Caspar Tudor in the audience as well. Udit, thanks for spending time with us.

Thank you, Vijay. Wonderful to be here, and thank you for inviting us to a warm location from the cold Northeast. Before we begin, I simply want to say, I get to do the blah-blah, but it's my team that does all the work, and they've been incredible through the year. It's a difficult environment, but I think the results show that we've been executing relatively well in this difficult environment.

Great. It shows in the numbers, right? It's -- clearly, we've seen a turn with some of the new end markets that you've entered in. Some of the growth accelerators we put in place. But maybe starting off with the macro that you did mention, it's been a challenging environment. And it's true for the space, right, not just Waters. Relative to those conditions that you saw in the third quarter, how would you characterize the macro environment right now? You say it's been in line with expectations.

I think you need to take a step back. And separate out China from the rest of the world, right? So for us, in particular, we've seen in outside of -- outside of China, we've seen things as expected, right? So let's just break it down between the end markets. I mean, Q3 was again sort of mid-single digit growth in pharma. I know that's stronger than many of our peers. I mean the funnel velocity is lower, so the orders are taking a bit longer, but the order quality is super high. And what do you expect after 2 years of really strong double-digit digit growth in pharma, yes, it's mid-single digit, and it's no problem, right? Industrial was negative in the quarter. But again, if you look at it on a stacked basis -- on 2-year stack basis, you're sort of lapping double-digit growth from last year. Industrial has no business growing high double digits for a long period of time, so it's sort of normalizing to mid-single digits. So what's wrong with that? And academic and government has been an exception, but that's due to the euphoria after the pandemic that many governments have funded academic institutions, and we're benefiting from that, and that was a high single-digit grower. So outside the U.S., things have gone pretty much according to expectations. And I know in pharma, especially our trends are a bit different than what you've seen for the rest of the industry. Now if you look outside of -- if you look in China, it's a completely different story, right? I mean we started the year expecting some sort of high single-digit growth, and we're going to end the year almost 25% down from where we started. And it started at the beginning of the year. I'm sure you'll have -- you want to get into that, so I won't belabor the point, but China has been across the board, getting progressively weaker as we've gone through the year. And we're starting to see some stabilization in a couple of segments, and I'll get into that when we discuss China. But if you take a step back outside of China, things are generally, as expected. Biopharma is doing well. The pipelines are exceptional. And I think you see a little bit of caution that is reflected in the longer funnels, but you don't see the order quality going down. And especially with our renewed portfolio, especially with very strong execution that we see in pharma in our deep relationship, especially in mid and large pharma, we're seeing some good results.

Great. And I did want to bring up one on the -- does book-to-bill for Waters sort of [indiscernible]?

No, it doesn't create any insight. I mean our customers are not waiting, especially for instruments that they use, again and again, they're not waiting more than 6 to 8 weeks to get an instrument. No instrument sits in the hallway in a box, right? So especially downstream, where we play, QA/QC or high-volume testing in food and environmental testing. So it really doesn't matter. By and large, if you want to get into it, I mean, orders have been growing in line with sales for us, for the last few quarters, right? And nobody has really asked about it, but for good reason, it's not insightful, right? So I think that's just an important metric to get out of the way early on.

That's helpful. So book-to-bill, what you're saying, it has been around 1x for Waters.

Yes,yes. Around 1x, and we'll end the year around 1, a little bit higher backlog. But again, nothing that I would say is exceptionally different from the past. And as I said, it's not insightful for our type of business. I mean it's insightful for contract manufacturing, for sure, right? Or for instruments that have massive lead times, but that's not where we are.

Understood. And before we get into China, I think the other topic which has been relevant for Waters has been the Q4 guidance and whether that's ramp, it contemplates historical seasonality, some others haven't baked in historical seasonality. There's been some confusion on the ramp. Maybe just walk us through your thought process on the Q4 guidance?

And I think, Vijay, I mean, we -- let me walk you through the algorithm, right? And we -- how -- what process we go through, and it's once in a while good to be fact-based, right? So I'll just share with you the facts that we use, and you can make up your own mind when you think about it, right? So starting with the first, which is uncertainty in the environment, right? So we've guided a broader range -- on a broader range than we've done in the past, right? So minus 8% to minus 5%, or in your terms, a ramp of about 13% to 17% from Q3 to Q4. So it's wider than it's been in the past, right? That reflects the uncertainty we see in the environment. Then what we do is we look at long-term historical trends, short-term performance and then try to make a judgment on where we are going to land. So if you look at the long-term trends from Q3 to Q4 at the lower end of the guide, which is 13% ramp, this is one of the lowest we've seen in the last 15 years, right? You have to go back to 2008 and '09 where we saw a 12% to 13% ramp from Q3 to Q4, right? So these facts are available for you to sort of do the same analysis. So he said, okay, 13% is a reasonable low end of the ramp. Then we said, okay, what have we seen in Q3? What are the short-term trends? And what have we seen in Q2? What have we seen in Q1? And what you see is a low single digit growth outside of China and increasingly deteriorating conditions in China, right? So what we've assumed is from Q3 to Q4, outside of China is a low single digit growth, continuing what we saw in Q2, what we saw in Q3. And that despite the fact that we have a 1 extra day in Q4 and a tougher comp versus Q3, we're assuming that it's going to be similar to Q3, right? So there's a bit of risk adjustment built there. And then China, we've assumed is going down 40%, in excess of 40%. So I don't see from a fact base that it's super risky what we're saying, and the range is wider. And then finally, as you -- I mean, you mentioned it as you compare it to peers, again, it's good to be fact-based. I mean if you look at, one, you have to look at apples-to-apples. There's no exact comparable portfolio, right? So I think one has to get a bit deeper. And if you do that, I don't see anybody doing anything different than what we're doing. And if you look at it at an aggregate basis, I mean, we've dropped at the midpoint, our ramp from 24%, which is what it used to be historically to about 15%. That's a 9% drop. That's actually steeper than most of the competitors if you just look at look at their drop in ramp, right? So I think one has to -- one can be fact-based and you can get underneath our thinking. And I understand there's anxiety on that, and I've heard that from others. But I mean all the others is transparent and fact-based and we said that in Q2 and Q3, and we're saying again in Q4.

And just to be clear, Waters did not assume any year-end budget flush in that guidance.

There is like -- as I mentioned, I mean, if you define the year-end budget flush as a ramp from Q3 to Q4, yes, there is a ramp from Q3 to Q4. By definition, the 13% to 17% is a ramp from Q3 to Q4, but that's always been the case. And as I mentioned, in the toughest years that we've seen in the last 15 years, that was a 12% ramp, right? And we're at 13% on the lower end of the guide. So I think it's not terribly aggressive.

Understood. And you did say ex-China before we get in to about China. Ex-China, the business has been up low singles throughout the year. Maybe just talk about what's been driving the ex-China trends. I think some of you peers are talking about IRA, pharma budgets coming down.

Yes. I think, again, it's good to look at the underlying trends, right? So we've grown mid-single digits and let's start with pharma first, and then we'll go to the other segment. Pharma, it's about 65% of our business. And again, we're talking ex-China. So ex-China, I mean pharma business, mid-single digit growth. One thing you have to keep in mind is we are more focused on QA/QC, which is downstream. And we've talked about this in the past, despite a slowdown in the economy, people don't stop consuming medicines, and we are proportional to the prescription rates of medicines. And I think that's the only metric you need to look at, and you find that our business is growing, sort of proportionately to it. It's mid-single digits after 2 years of double-digit growth, right? So you can see that there's a bit of normalization. Then if you move into industrial, industrial in Q3 was negative, but on a stacked basis, it's still mid-single digits. It's about 6% growth. And long term, industrial is a mid-single digit grower. Even if you include some of our faster-growing segments, which are pretty small at this point. And academic and government, outside China, grew high single digits -- mid- to high single digits. And this was, again, sort of consumption of funding that came from governments in Europe and in the Americas, right? So really happy with the performance ex-U.S. and it's gone according to expectations. And especially in pharma, it's a reflection of all the new products that have come in, being really close to customers and the natural leaning towards high-volume applications in QA/QC. I think that explains why our results would be a bit different. So new products and QA/QC in particular, and great execution as a consequence.

Fantastic. And so far, would you say the trends we've seen, ex-China has been in line with broadly with expectations?

Yes, I think not much different, right? So if you -- another way to think about it is, I mean, we started the year -- and I mean if you just look at how much you've taken down guidance from the beginning of the year to now, at the midpoint, it's about 700 basis points, 6%, 7%. 6% to 6.5% of that is China, right? Even though the funnel velocities have slowed down in the segments that we serve with the new products that we have, we are not seeing a dramatic change versus what we came into the year with. And we expected the year to be a little bit slower given the comps that we had, right? So it's not terribly different.

Understood. Understood. And I think some of us have tried to do those CAGR resources pre-pandemic. So when you look at the ex-China pharma business CAGR, if that's been running above the long-term mid-single trend, is that perhaps some exuberance related to pandemic-related spending, should come out of the system?

Yes. I think it's difficult to sort of parse out, in our case, in particular, was it a push out from -- remember, we started our transformation in 2020 in the middle of the pandemic. And we launched our commercial initiatives. We saw exceptional growth coming out of it. The market also started to pick up at the same time. I think a lot of that was attributed to the fact that we had not executed well commercially from 2018 to '20. And so we started to see that catch-up rather than pull forward, right? And we talked about it at that time. Second, our new products gained a lot of traction, right? We launched a whole bunch of new products. They gained a lot of traction and they contributed. And I think the underlying market was, yes, a bit higher coming out of the pandemic, right? So I don't know how much of that is push out or how much of that is pull forward. In our case, we could explain a lot of it by sort of the push out from the pre-pandemic days. And I think as you think about the future, which is rather more important now, I mean, the way I would look at it is, especially for Waters, over the long term, our instrument business is a mid-single digit grower, say, 5%, 6%, right? And as you look ahead, you see better pricing. You see new products that have been launched during this pandemic era in a CapEx constrained environment, but they're still gaining traction, and new products usually start to reach their peak sales in 3 to 5 years, especially instruments, too. It takes that much time. So you had a time to sort of ingest and seed all these instruments across the industry, and they are really waiting to take off as the CapEx constraints come off, right? So you see better pricing. You see a completely renewed portfolio on the instrument side. And you see newer applications in biologics, in PFAS testing, in battery testing, where we are incredibly focused. So I would think of the instrument business growth over the midterm -- mid to long term, sort of traversing towards the high single digits, right? And I think that's something new and we're pretty excited about it, and we think that is where we can get to. Consumables or the recurring revenue has been growing high single digits all the way through even during the slowdown, right? So there's -- the long-term algorithm is pretty robust, right? I cannot judge what the fluctuations are every quarter. People smarter than we would have to figure out exactly what they are. But I think mid- to long term, feel really good about where we are. And especially the additional confidence that our teams have now having executed during a very difficult time and executed well.

Sorry, and just to clarify, Udit, you said the longer term -- medium to longer term, instrumentation should be above the mid-singles? Is that what you said?

It starts off at mid-single, but I think you look at better pricing on top, right? You look at newer products on top and you look at more applications. So you're looking at mid- to high, high single digits. I'm not here to sort of give you exact long-range plans, but all I can tell you is I feel good about where we are with our portfolio and the execution on the instrument side, and the recurring revenue has been doing well anyway.

Fantastic. And since you brought up newer applications, Udit. I think we've seen some headlines about some of these EV companies scaling back on battery investments in new plants. Does that impact Waters?

I think, eventually, sure. But the adoption of new instruments in that space is so low today, Vijay, right? I mean we've spent a lot of time in China, in particular, talking to customers there. And there, the adoption is increasing much faster than it is in the rest of the world because they are much further along in the cycle of development of electric vehicles and batteries, right? And we're seeing significant adoption of our thermal analysis, mechanical analysis products and product characterization and process development and raw material characterization, not as much in QA/QC, but we'll see that trend over time, right? It will start in China, it will go to the rest of the world. Yes, it's likely to be a cyclical industry, but we are far from having seen an impact. I mean we're such a miniscule portion of their spend today that it doesn't even impact -- it doesn't get impacted by the macro cycles that they will see.

That's helpful. And before we go on to new products and some of the momentum you're seeing, I did want to touch upon China. Maybe talk about China. I know you were in China recently. And it sounded like based on what some of your peers are saying, maybe China trends aren't incrementally worse. I mean, it looks like we're around the bottom. Would that be a fair statement?

I mean, I don't mean in generalities when we can be specific, right? Let's just look at China as a the whole. And I was there in August, and we were pretty precise about what we had seen. So let me sort of repeat some of that and talk about where we are in that set of trends. So start with pharma, which is about 65% of our business in China. We started -- and again break it down into different segments, roughly 15% of our sales in China are biotech. Another 35% is sort of contract manufacturing. And the remaining 50% is branded generics, okay? So let's take each of these in turn. The biotech piece really hit a wall at the beginning of the year, and that 15% basically dropped down by 80% of that number, right? So it's bottomed out at 20% of that 15%. And that's really, I would call it, a structural change. All sort of the poor molecules, the ones that were not supposed to be supported are no longer supported, and that's fine, right? That's flushed out of the system. That's about, say, $50-ish million in sales that's, I think, gone, right? The rest of it -- the rest of the 90% of the business is still there, and it will come back, right? So then if you go into contract manufacturing, we started to see, again, a headwind in Q1, when the overcapacity that was buried during the pandemic and the geopolitical tensions had our customers sort of take some of the capacity and move it out of China into Singapore, into Ireland into other geographies. And that has happened to a large extent. And we're already seeing volume in Singapore and Ireland. So while the bricks and mortar are still there, the utilization of the contract manufacturing facilities is again increasing, right? And we can tell because we see our recurring revenues increase at those customers, right? And we're again a victim of our own success in that particular segment. We had grown by about 40% to 50% in that segment over a 2-year period and really super successful. And then when it came down, of course, got impacted by it. And the third segment is the branded generics segment, where the customers are very used to value-based pricing, right? When the price drops by the government and they sort of adjust their SG&A modestly, they adjust their pricing modestly and they're able to deal with it, especially the big customers in that segment. But when the anticorruption campaign was launched during the summer, that came as a surprise. And the sheer speed at which it was implemented came as a surprise to many of the customers. Now that, to some extent, has rolled out already in the large cities in Beijing and Shanghai, where a lot of the party officials also live, right? I mean there, the anticorruption campaign has gone through and the hospitals are starting to procure again, right? But outside of those large cities, it's still very much in progress, right? So if you ask me to predict what's happening in pharma, for us, in particular, biotech has bottomed out and we'll start to see it come up. On the contract manufacturing side, don't expect a lot of CapEx, but the recurring revenue piece is starting to pick up already. And on the branded generic side, it depends on which city you're in. In Beijing and Shanghai, you start to see a pickup. But in the other cities, you're still waiting, right? So it's not over yet in pharma. Outside of pharma, I mean, industrial has been growing rather nicely. But then that's a food -- especially the food and environmental segment, which is bulk of our industrial exposure and materials segment are dependent, especially food and environmental is dependent on government funding. And that scales with the macroeconomic trends. And so as the GDP rises, you'll see that go up. And when it falls, you'll see that go down a little bit. And that's largely true in China because it's -- the food and environmental testing is mostly funded by the government. And then in the food -- in that industrial segment, the PFAS testing and the battery testing segments are too small to have a meaningful impact at this stage. The academic and government segment, we saw significant benefit in the first half of the year from the funding that came late last year. There could be another stimulus. But honestly, I don't know what these large universities are going to use that for. You go there, then they bought everything. And when I visited this summer, I can tell you, they have some of the best and the highest quality instruments that you would not find at a Caltech or a Princeton in the U.S., right? The sheer quantity of those. So I don't think -- and we've talked to them recently. In fact, yesterday, I was on the phone with our China head, and he was saying, "Look, these top universities, they don't know what they're going to do if they get additional funding. But Tier 2, Tier 3 universities, probably could use the funding, right? If there's another stimulus." So I do think the academic and government segment will go back to its long-term growth rate, which is 2% to 3% in the next year or so, right? So that's the set of assumptions we have. I've tried to be as granular as I can be, and I hope that answers your question on where we see a bottom and where we see a rise, but it's not a straightforward answer. Say, well, everything is bottomed out and everything is going to go up, I wouldn't be so brave at this stage.

That's extremely helpful color, Udit. I mean, it certainly feels like relative to guidance assumptions, this is pretty much in line. Your guidance, I think, for China assume the exit rates, trends that you saw, and these are pretty consistent with those trends.

Yes. Absolutely. And I think what I don't want you to take away is that we are sort of exiting China. Far from it, right? If you -- and I think this is the primary insight. If you take a step back in pharma, and you take -- you look at everything that's taking place through the lens of innovation. The government wants to fund only bonafide new products. right? They don't want the 20th PD-L1. They don't want a copycat mRNA. They'll fund new bonafide molecules. And they want to invest in the infrastructure that is going to support taking a molecule from filing all the way to launch, right? So what is missing in the economy, they have great manufacturing, they have great commercial execution with the branded generics segment. The biotech segment is picking up, but what's missing is translational medicine. By translational medicine, I mean the regulatory departments and large companies, the CMC departments, the clinical development and clinical pharmacology departments. That infrastructure has to be built, and that's fantastic news for somebody like Waters, right? We work very closely with our customers to establish that infrastructure. We did that with Merck, Pfizer, et cetera, outside of China. And we'll do that with local competitors and local players in China over the next few years. So counterintuitively, we are actually increasing our investment, not just in manufacturing in China, but also in technology development, right? And it sounds counterintuitive when you look at the macro trends. But if you truly understand what's happening at a deeper level, and what the government is doing, what the provinces tell us, it's clear that they want to fund innovation. And if you go in and say, we're going to help you develop an innovative -- take an innovative molecule from discovery to the clinic to patients, I think you get support, right? And so I don't think China is going to remain sort of difficult for a very long period of time. And I mean, you have to just look at the demographics, right? It makes total sense that it's going to come back. It's just a matter of time.

Yes. And how long have these cycles lasted historically, Udit?

How do you mean cycles?

In China, when China goes through these kind of -- yes.

This is -- I mean, so I've been in the tools industry since 2013 or '14, so 10 years or so. China, when it goes down, usually comes back violently fast. This is the first time we've seen a prolonged period of slowdown, right? So don't ask me how fast it comes back, when it comes back. I feel much more comfortable being granular with segments and with products than making a broad prediction. I think for us, we are not reducing our overall infrastructure. Of course, you adjust the cost base as the volume goes down on the variable side. But overall, we're going to be looking to partner with our customers as they pick up. And the other one that I didn't talk about is the clinical segment. right? That's doing super well. I mean, you remember, 1 of our 5 adjacencies was taking mass spec in to the clinical segment. And that business has gone from about a 3% grower to about a 15% grower in the last 2 years, despite the fact that the whole economy has slowed down.

That's fantastic. And maybe last question here on China. What is your China revenue base? What is the CAGR versus 2019? And I think some of your peers related, when they look at the forward outlook for China, they still expect to be accretive to corporate but perhaps below the past decade? How are you thinking about China bigger...

I think just -- I mean you -- I suspect you want to start from the 2019 to '22-ish '23-ish CAGR. The business will be in line with what we saw in 2019, about 1% smaller, right? So it's been a pretty significant decline. And if I just give you the magnitude, we started the year at $550 million, when China was about 19% or 20% of our business. We'll exit the year slightly north of $400 million, okay? That's a 25% drop, right? If you take FX into account as well. And you will now -- China will now be about 11% to 12% of our overall business, so less as a weightage. So there has been a significant drop in China over the year. And as we now look at the long-term trends, right? So from 2005 to say, to 2022, China grew 16% CAGR. Rest of Waters grew 5%. And and overall Waters was growing 6%. China added 100 basis points of incremental growth versus the rest of the business for the last 15 or so years. If you just look at it from 2020 to 2022 since we launched our -- and this is a really important point. Since we launched our transformation, China has grown at a 9% CAGR as has the rest of the business. So it's not that China has slowed down. It's the rest of the business has picked up, right? And they're growing in line with each other, right? Now going forward, we do expect China to be accretive to go from this $400 million and start to pick up pace, and we do expect China to be accretive, but the rest of the business has also picked up pace and it's also pretty healthy, right? And you saw that this year, right? I mean you saw the rest of the world actually doing pretty well, whereas we saw a drop in China, and that helped us also offset the challenges we saw on the cost side.

Understood. In some of the new applications, you did bring about PFAS testing. I think given where we are on regulations, has the size of that end market changed? And what does Waters' position in PFAS?

I mean -- I think we had sized it to what, $200 million, $250 million. I suspect it grows every day as the applications increase. And that only included water testing, to some extent, a little bit of food testing, but there's now tissue testing, there is testing of sewage. There's demand from industrial companies who are replacing PFAS with other molecules. So we're in the very early innings of the penetration of our instruments, our consumables, our systems in PFAS testing. And we're growing north of 40% in that segment. Now if you look at the overall industrial segment, this is a much smaller portion of it today. Over time, it will grow. And we're investing a fair bit in this segment. And you'll hear more about innovations in that area.

Understood. And would you say that Waters has a leading position within PFAS ecosystem?

Definitely, from an instrument perspective, we have, by far, the most sensitive mass spec instrument in the industry, and the EPA has adopted our instrument as well. I think as you look at the broader set of offerings, the sample prep, the automation, we are building our strength there. But usually, people start with the instrument. They say, I want the most sensitive instrument because the EPA is raising the standards on it every day, right? And we can detect 1 per quadrillion, which is well above what they're asking for today, but we think the regulations are going to increase, and they're asking for increasing the larger number of molecules to be tested. So that bodes well for our chemistry business. But I do feel it starts with the instrument itself. And there, by far, we have the most sensitive instrument.

And I think -- sticking on with that new applications or perhaps new opportunities, GLP-1s have come up. I think in the past, you said you work with the major players in the industry, but how do we size the opportunity for Waters?

Early days to dimensionalize it, Vijay, right? I mean we're -- when you saw -- I suspect you saw the announcements from one of them, $2 billion in one country, another $1 billion in another country from a manufacturing site. Each manufacturing site comes with QA/QC. All I know is respect into we're the leading player in columns for both of the innovators there, and our LCs are used in QA/QC as well. And increasingly, they're using our patrol system, which is a process analytics tool so in-process testing for manufacturing. So we are very well placed. Over time, we'll start to dimensionalize this more, but give us a little bit of time to start seeing some early trends and then again, do it in a fact-based space rather than just a top-down projection.

Understood. Would that suffice to say, like given these manufacturing plants or the investments are being paid -- made, we've seen some orders coming from the segment.

Yes. For sure. For sure. No question. And those are not orders that -- those orders, the funnel velocity is much faster than the average funnel velocity that we've seen, right? So those orders come, and the customer wants the product immediately.

Got you. And you did bring up government and academia. Governments have spent around the globe. Is there a risk -- the close, I can think of is sequestration last time around something like that happening?

I think -- I don't -- I won't use the word sequestration, but I would not assume, especially -- we talked about China at the beginning. I would not expect that, that level of funding can be consumed by academic institutions, right, what we saw in China. We're still seeing increasing funding in the U.S. We're seeing increasing funding in Europe to start to flow through the different academic institutions. But I don't expect this market to be a double-digit grower for a long period of time, right? I mean it will likely to reverse back to the low single digit growth. But I wouldn't use the word sequestration.

Got you. So even though the comps are tougher, the view was we still expect to grow, perhaps more at a normalized level?

Yes, I would think. I would think you -- I think, again, you would have to look at the long-term growth rates and say how fast do we get to the long-term growth rates probably in the next year or 2 years, you start to see that.

Got you. And then one on industrials. What is Waters exposure, cyclical end markets?

So again, I mean, I think overall, industrial is about 30% of our business. And when you look at PFAS testing or battery testing, that's 5% to 10% of that particular business, and that's growing well north of 30% to 40%. The rest of it, which is food and environmental, primarily in materials testing and a little bit of electronics. That basically is a mid-single digit grower. So again, if you look at our ex-U.S. growth, it's mid-single digits on a 2-year stack basis, which is where you should expect it to roll, right? And I don't -- again, I think that will -- that is starting to normalize. We saw significant growth coming out of the pandemic, but that's starting to normalize even in industrial segment.

Understood. Some of the new products, Udit, you mentioned, carrying higher pricing, potential to gain share. BioCore, I think, comes up in the past. And there have been several new products, right? Even on the mass spec side. Like what excites you from a new product perspective?

Waters heart beats with new products. I mean we're a company that loves to go after very, very difficult problems, very difficult unmet needs. And when we get a proof of concept, we try to talk to our customers sooner than later, right? Many examples of this, right? I mean the prime example is when you look at our pharma exposure, 2, 3 years ago, less than 20% of our business was in biologics. That number now is in excess of 35%, okay? And pharma is our largest business. It's wonderful in your career if you see over a short period of time that you start something and it starts to show impact that quickly, right? I know markets have been going up and down, but that's fantastic, right? To go from 20% -- less than 20% to 35% in a faster-growing area, where we were very open about what we're trying to do. We wanted to increase our investment in bioseparations. So 80% of our investment in columns is now on biologics, right? And you see that impact with MaxPeak. Premier Columns, which in its third year after launch, is growing between 20% and 30%, depending upon geography. We just launched a new column that works very well with our wired instruments. It's an SEC malls column, it's an SEC column, especially designed for AAVs, right? Then we bought Wyatt, which increased our exposure in that faster-growing segment. So it's very deliberate. We were very open about what we're trying to do in the separations area, in the analytical instrument area and the analytical instrument area you talked about BioAccord. Darn difficult problem to solve, to take a mass spec that is super complex, and I'm an engineer. And I don't -- well, now I love analytical instruments that are simple. But prior to this, jeez, I was running away from analytical instruments because they are so difficult to use, especially mass specs. We wanted mass specs to be easy enough to use, so we could put them into the process development space. And we've done that in raw material testing, in upstream bioprocessing and downstream bioprocessing with BioAccord and many other sort of ideas around it, with automation and our collaboration with Sartorius. So it's a difficult problem to solve. It's -- these instruments, when they have to be adopted, the first step is to simplify them and have the customer try them. So we've already done that. So in raw material testing, you have Janssen as a leading customer. In upstream bioprocessing, you have AstraZeneca. Downstream in QA/QC, you have Regeneron, so leading players. And once they adopt it, and they start using it, we don't need to do anything, right? Then the others follow. And so we are in that sort of zone. And given the CapEx constraints, you see that sort of a bit muted, but that will pick up. So really excited about what we're seeing in -- with the application of BioAccord and simpler mass specs. High-res mass spec, I mean that's an area where we had struggled in the past. We've sort of focused now more on metabolomics and imaging. That's done pretty well over the last few years and the Xevo TQ absolute for PFAS testing. So mass spec is doing extremely well. It's an innovation-sensitive market, and it's a place where Waters is making a difference, especially going into more difficult applications. LC, we launched the Alliance iS. I mean, it's the most meaningful advance in high-volume LC testing in over a decade, right? Where you reduce errors by 40%. And we're seeing, again, customer adoption. I mean the CapEx is constrained in many of our customers. But even so, Janssen has purchased and replace their fleet with the Alliance iS. As they do it, the others start to do it over time. So we're seeing adoption of the Alliance iS as well. And columns, as I mentioned earlier, 80% of spending is going towards biologics. And lastly, in the battery testing space, again, our TA business has pivoted very nicely, moved towards taking our thermal and mechanical analysis instruments and moving them into kind of battery testing spaces.

A lot to unpack there, but you did bring up clinical diagnostics. I think one of your diagnostic peers yesterday -- or I guess, day before yesterday sounded pretty bullish about launching a new system next. What is Waters within clinical diagnostics?

So I mean, we are focused on specialty diagnostics, right? So we want mass spec to be the tool of choice for early disease detection of trace biomarkers -- with using trace biomarkers, right? And we've been, of course, successful with newborn screening. We're now -- we've now developed sample prep and analytical techniques for endocrinology for drugs of abuse. We're looking at early-stage cancer detection, and we're working with some of the key pharma players on detection of the tau and beta amyloids for Alzheimer's detection. So very excited about it. And we've recently signed an MOU with a key player in China to take our mass spec and build it into a system so that it's available for high-volume testing as well. So again, very excited. And again, fact speak louder than words. That business itself was growing 3% from 2018 to '20. From '20 to '22, and year-to-date, it's in excess of 15%.

Those are growth numbers?

Those are growth numbers, top line growth. And we've -- as I said earlier, we've invested in that area. And again, this is despite the fact that we will exit the year with a 30.5% operating margin. right? So in a year where we have lost about 700 basis points from the beginning of the year to the end of the year, on top line, we managed to expand our margins, and that is no small feat. That reflects the discipline in the company by about 30 basis points, in fact, after investing in these high-growth areas.

Should '24 margin expectations look similar or...

We're even 5 minutes to go, and I was expecting this question in the first 3 minutes. So you've been very patient. I'm not speaking about 2024. I think you know that. There's -- for Waters, Q4 is the largest quarter. The last 5 weeks are the largest weeks in the whole year, let that unfold. We're working through our projections, and I gave you all the algorithms, so I was very granular on what data we look at. You can probably look at that sort of data and start thinking about what it would be like. We look at historic trends. We look at how we're exiting each of the different quarters. We're looking at funnel velocity. And we're doing it very granularly and then building it up and then putting some risk adjustment on top. But that is ongoing now, Vijay.

Or maybe asking differently, Udit, like what are the levers we should be thinking? Like should pricing still be a good guy? Should inflation in FX be a bad guy? Maybe just some detail.

Yes. I think the FX assumption, I think we can talk off-line a little bit about, but on the building blocks, right, we expect pricing to continue to be a strong lever. And this is because we've sort of implemented new systems during the pandemic, during the time where there was a supply chain issue. We implemented new processes. We don't expect that to change. And this year, we'll exit with 250 basis points of pricing, a bit higher than that as in fact. So we're expecting pricing to be a positive contributor due to operational excellence and the new products. New products will start to come into the base, and they're definitely at a higher price point, right? So that piece is clear. On the volume side, I think we walked through the different levers, and we'll go market by market. We'll look at what's happening in pharma. We talked about China, where we said, look, there is sort of a bottoming out of 2 or 3 segments, but we still are seeing a downward trend in one segment. Outside of China, we've seen sort of a normalization of growth to historic trends, right? And there, again, that's a useful assumption to keep in mind, right? So we've been growing mid-single digits in pharma. We think Industrial will sort of come back to normal. Academic and government will come back to normal, despite the fact that it has pretty significant comps. So I think that's sort of the algorithm on the volume side. Keep China out and do ex-China, use the same logic that we've described today, and you come to something meaningful, but we'll guide when we deliver our Q4 results. A lot of time until then.

Fantastic. I think you guys initiated some cost actions this year. Should that -- is it all done in fiscal '23 audit? Or is there some incremental benefit next year?

So there is definitely incremental benefit next year, right? So there is -- it's about $20-ish million this year, there's an incremental $20 million or so next year. But we will take a look at that as we look at our operating plan and see how much of that we want to reinvest for growth. And as I think you'll agree with me that all these growth areas are paying pretty nice dividend. So we want to continue that trend.

Great. And I know usually in these forums, sometimes like we'll look at near-term macro trends. But from your perspective, what is the one message you want investors to walk away with? What is it that I should have asked bigger picture and did not ask?

Yes. I think you asked everything. And so it's a very comprehensive discussion. What I would leave you with is the long-term growth algorithm for Waters, right? I mean we're a company that has been growing 5%, 6% for a very long period of time. And you take 2 building blocks of our business, instruments and recurring revenue, instruments historically have grown 5% to 6%. But now we're in an era of better pricing, we're in an era of newer products, which are just starting to pay dividends, and we're seeing more applications in faster-growing areas. So we're seeing benefit of our growth initiatives. So instruments should grow faster than the mid-single digit growth that we've seen in the past. Don't ask me if it is 7%, 9% or 10%, I don't know, but it's higher. And recurring revenues have been doing very well. And we've pivoted towards more faster-growing areas, there to 80% of our R&D, 70% to 80% of R&D investment in columns is going to biologics. Attach rates and service have been going up. And remember in 2020, we talked about 1,000 basis points, we're already more than halfway down that journey. And each 100 basis points that you add in service over the midterm adds 100 basis points on service growth, right? So it's a significant driver. So we feel very good about our long-term growth algorithm. And then on the cost -- on the bottom line, what you need to know is Waters is a very financially responsible company. I mean you see that this year. We will take proactive actions, and we will take them to preserve the margins and our flexibility to invest. I mean, not many people are able to grow their margins after investing significantly in the 30 basis points that you've signed up for even this year is a testimony to that. So very happy with the team. Our culture is that of innovation. And I think the long-term algorithm is a pretty robust one. So thank you again for having us.

Fantastic for that. We're out of time. Udit, thanks for the time this morning.

Thank you, Vijay.